



Average FY Product Sales Consensus

€m	2019a	2020e	2021e	2022e	2023e	2024e	2025e
Core Products							
Cimzia	1,712	1,837	1,924	1,974	1,956	1,821	1,552
Vimpat	1,322	1,455	1,565	1,392	862	659	528
Keppra	770	738	696	632	581	539	505
Briavact	221	295	364	429	490	544	589
Neupro	319	300	257	203	167	142	122
6 Potential new product launches (global sales, non-risk adj.)							
Evenity (romosozumab)		388	536	670	809	932	1,017
Midazolam nasal spray		19	40	59	77	90	99
Bimekizumab		0	67	230	440	639	907
Rozanolixizumab (Rozimab)		0	3	41	120	263	433
Padsevonil		0	4	25	89	176	273
Anti-Tau		0	0	0	0	84	196

*until 2025

Median FY Product Sales Consensus

€m	2019a	2020e	2021e	2022e	2023e	2024e	2025e
Core Products							
Cimzia	1,712	1,841	1,920	1,986	1,945	1,808	1,554
Vimpat	1,322	1,434	1,542	1,411	918	717	540
Keppra	770	740	683	625	579	529	486
Briavact	221	299	369	429	491	546	586
Neupro	319	308	258	202	172	144	120
6 Potential new product launches (global sales, non-risk adj.)							
Evenity (romosozumab)		405	525	662	806	914	1,000
Midazolam nasal spray		18	40	60	80	100	112
Bimekizumab		0	67	210	401	621	809
Rozanolixizumab (Rozimab)		0	0	30	100	243	416
Padsevonil		0	0	19	80	182	274
Anti-Tau		0	0	0	0	108	245

*until 2025

Based on the estimates of 14 brokers

Last updated: 06/03/20